Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4

Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4

US Patent 11285145 · Granted Mar 29, 2022

Estimated economic value: $25,073,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with2025
Treatments for amyotrophic lateral sclerosis using dazucorilant2025
Treatments for amyotrophic lateral sclerosis using dazucorilant2025
Glucocorticoid receptor modulators to treat pancreatic cancer2025
Glucocorticoid receptor modulators to treat cervical cancer2025
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators2025
Fatty liver disease treatment using glucocorticoid and mineralocorticoid recepto2025
Quaternary indazole glucocorticoid receptor antagonists2024
Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors2024
Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor 2024
Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators2024
Octahydro fused azadecalin glucocorticoid receptor modulators2024